Zacks: Brokerages Expect Agenus Inc (NASDAQ:AGEN) Will Post Quarterly Sales of $5.37 Million

Equities analysts expect Agenus Inc (NASDAQ:AGEN) to announce $5.37 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Agenus’ earnings. The lowest sales estimate is $1.43 million and the highest is $9.30 million. The firm is scheduled to issue its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Agenus will report full-year sales of $69.53 million for the current financial year, with estimates ranging from $16.50 million to $107.90 million. For the next financial year, analysts expect that the firm will report sales of $15.42 million, with estimates ranging from $2.76 million to $27.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that that provide coverage for Agenus.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.42. The business had revenue of $8.61 million for the quarter, compared to analysts’ expectations of $9.03 million.

A number of analysts recently commented on AGEN shares. B. Riley began coverage on shares of Agenus in a research note on Monday, April 22nd. They set a “buy” rating and a $5.00 price target on the stock. BidaskClub lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Friday, April 19th.

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank bought a new position in shares of Agenus in the 4th quarter worth $30,000. Two Sigma Securities LLC bought a new position in shares of Agenus during the 4th quarter valued at $31,000. Legal & General Group Plc grew its holdings in shares of Agenus by 47.7% during the 4th quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 7,002 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Agenus by 80,579.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 19,339 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new position in shares of Agenus during the 4th quarter valued at $80,000. 33.08% of the stock is currently owned by institutional investors and hedge funds.

Shares of AGEN stock traded up $0.03 during trading on Thursday, reaching $3.04. 4,587,723 shares of the company’s stock traded hands, compared to its average volume of 1,344,875. The company has a market capitalization of $408.82 million, a P/E ratio of -2.11 and a beta of 1.82. The stock has a 50-day moving average price of $2.81. Agenus has a 1 year low of $1.54 and a 1 year high of $3.88.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Article: Asset Allocation Models, Which is Right For You?

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.